LYFE Sciences · Project HERA
Variant Interpretation · Classification Report
Generated: 2026-11-20
Case ID: NM_000051.4_c.8921C_T_20261120_015030
Framework: ACMG/AMP 2015
Variant classification summary

NM_000051.4:c.8921C>T

ATM  · NP_000042.3:p.(Pro2974Leu)  · NM_000051.4
GRCh37: chr11:108235879 C>T  ·  GRCh38: chr11:108365152 C>T
Gene: ATM Transcript: NM_000051.4
Final call
Likely Benign
PS3 supporting PS4 strong BS1 strong BS3 supporting BP4 supporting
All criteria require review: For research and educational purposes only.
Gene
ATM
Transcript
NM_000051.4
Protein
NP_000042.3:p.(Pro2974Leu)
gnomAD AF
9.788627597238864e-05 (v4.1)
ClinVar
Uncertain significance
OncoKB
Likely Oncogenic
Interpretation summary
Generated evidence synthesis
1
Pathogenic evidence: PS3 supporting reports impaired ATM phosphorylation and DNA-repair rescue.
2
Pathogenic evidence: PS4 strong reports 13/7,204 cases versus 0/9,593 controls with p=1.7 × 10^-5.
3
Likely Benign: BS1 strong is met because gnomAD v4.1 grpmax filtering AF is 0.193551%, exceeding 0.05%.
4
Likely Benign: BS3 supporting reflects a direct prime-editing Functional result with High confidence.
5
Likely Benign: BP4 supporting is met by REVEL 0.148, below the VCEP cutoff of 0.249.
Final determination: Under the ATM VCEP Version 1.6 framework, BS1 at Strong satisfies Rule20 for Likely Benign, with BS3 and BP4 also satisfying Rule19, and no pathogenic rule is met.
ACMG/AMP criteria review
Criteria shown when status is available
All criteria require review: For research and educational purposes only.
Criterion Status Rationale Evidence used
PVS1 N/A Not applicable: c.8921C>T is a missense SNV (p.Pro2974Leu) in exon 62, not a PVS1 null-variant class.
vcep_suppl_tables1_pmid_40580951 vcep_atm_pvs1_1_6
PS1 Not met Not met: ATM PS1 requires a previously established pathogenic variant with the same amino-acid change, but ATM_PS1_1.6 has no c.8921C>T, p.Pro2974Leu, or p.P2974L entry.
cspec vcep_atm_ps1_1_6
PS2 N/A Not applicable: the ATM VCEP marks PS2 not applicable, and the variant-specific report documents paternal inheritance rather than a de novo event.
cspec PMID:12511424
PS3 Met Met, Supporting: variant-specific studies show reduced ATM phosphorylation and impaired DNA-repair rescue, while Sun et al. reports Functional in direct prime editing.
cspec vcep_suppl_tables1_pmid_40580951 PMID:40580951 PMID:12511424 PMID:31160347 vcep_clingen_hbop_atm_supplementary_tables_1_and_2_v1
PS4 Met Met, Strong: 13/7,204 cases versus 0/9,593 controls, p=1.7 x 10^-5 <= .05, corrected OR=36.018, and lower 95% CI=2.141 >=1.5.
cspec PMID:31160347
PM1 N/A Not applicable: the ATM VCEP explicitly marks PM1 as Not Applicable, and no authoritative ATM domain-table entry is present.
cspec
PM2 Not met Not met: the highest gnomAD v4.1 subpopulation AF is 0.22949% (103/44882), exceeding the VCEP PM2 threshold of <=0.001%.
cspec gnomad_v4
PM3 Not met Not met: the exact variant was heterozygous in a leukemia patient, with paternal inheritance and no reported A-T diagnosis or pathogenic ATM variant in trans.
cspec vcep_atm_pm3_bp2_1_6 PMID:12511424
PM4 N/A Not applicable: the variant is a missense substitution, whereas the ATM VCEP limits PM4 to stop-loss variants.
vcep_suppl_tables1_pmid_40580951 cspec
PM5 N/A Not applicable: PM5 is limited to NMD-prone truncating variants with PVS1 Very Strong and premature termination codons upstream of p.Leu3048, whereas this is missense.
cspec
PM6 N/A Not applicable: the ATM VCEP marks PM6 not applicable, and the reported variant was inherited from a heterozygous father.
cspec PMID:12511424
PP1 N/A Not applicable: the VCEP limits PP1 to autosomal-recessive segregation in affected relatives, while this report shows paternal inheritance without qualifying affected-relative segregation.
cspec PMID:12511424
PP2 N/A Not applicable: the ATM VCEP explicitly marks PP2 as Not Applicable, so no gene-level missense-mechanism evidence can be assigned under this framework.
cspec
PP3 Not met Not met: REVEL 0.148 is below the >0.7333 PP3 threshold and SpliceAI maximum delta 0.006 is below the >=0.2 threshold.
cspec vcep_suppl_tables1_pmid_40580951 PMID:40580951 revel spliceai
PP4 N/A Not applicable: the ATM VCEP explicitly marks PP4 as Not Applicable.
cspec
PP5 N/A Not applicable: the ATM VCEP explicitly marks PP5 as Not Applicable.
cspec
BA1 Not met Not met: gnomAD v4.1 grpmax Filtering AF is 0.193551%, below the VCEP BA1 threshold of >0.5%.
cspec gnomad_v4
BS1 Met Met, Strong: gnomAD v4.1 grpmax Filtering AF is 0.193551%, exceeding the VCEP BS1 threshold of >0.05%.
cspec gnomad_v4
BS2 N/A Not applicable: the ATM VCEP says not to use BS2 because ATM has incomplete penetrance.
cspec
BS3 Met Met, Supporting: Table S1 directly measures the variant as Functional with High confidence, but published assays report abnormal ATM activity and require human review.
cspec vcep_suppl_tables1_pmid_40580951 PMID:40580951 PMID:12511424 PMID:31160347 vcep_clingen_hbop_atm_supplementary_tables_1_and_2_v1
BS4 N/A Not applicable: the ATM VCEP marks BS4 not applicable, despite the heterozygous father being free of malignant disease at publication.
cspec PMID:12511424
BP1 N/A Not applicable: the ATM VCEP explicitly marks BP1 as Not Applicable, so no generic benign missense-location evidence can be assigned.
cspec
BP2 Not met Not met: no cis or trans pathogenic-variant observation in an unaffected adult was reported for this heterozygous variant.
cspec vcep_atm_pm3_bp2_1_6 PMID:12511424
BP3 N/A Not applicable: the ATM VCEP v1.6 CSPEC explicitly marks BP3 as Not Applicable for this assessment framework.
cspec vcep_suppl_tables1_pmid_40580951
BP4 Met Met: missense REVEL 0.148 is at or below the VCEP BP4 cutoff of <=0.249.
cspec vcep_suppl_tables1_pmid_40580951 PMID:40580951 revel spliceai
BP5 N/A Not applicable: the ATM VCEP explicitly marks BP5 as Not Applicable.
cspec
BP6 N/A Not applicable: the ATM VCEP explicitly marks BP6 as Not Applicable.
cspec
BP7 N/A Not applicable: p.Pro2974Leu is a missense substitution, whereas BP7 is limited to synonymous or deep intronic variants.
cspec pvs1_variant_assessment
Disclaimer: The content and results provided by LYFE Sciences are for research and educational purposes only and must not be used as a substitute for professional medical judgment, diagnosis, or treatment. Always consult a qualified healthcare professional before making any clinical decisions.